Showing 4 posts of 4 posts found.

Novartis HQ

Novartis signs experimental eye drug deal

March 19, 2012
Research and Development, Sales and Marketing Novartis, ThromboGenics, vitreomacular adhesion

Novartis will develop an experimental eye drug with ThromboGenics in a pact worth nearly $500 million.  The deal has been …

Eye treatment could be commercial breakthrough for ThromboGenics

September 1, 2010
Research and Development ThromboGenics, eye care, microplasmin

Belgian biopharma company ThromboGenics could have a major product on its hands in the shape of new eye treatment. The …

Blood clot

Encouraging data for ThromboGenics and BioInvent product

May 7, 2010
BioInvent, Lovenox, ThromboGenics, VTE

An antibody-based drug to prevent blood clots after orthopaedic surgery has shown promising results in phase II. TB-402 is a …

Latest content